BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7101129)

  • 1. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response.
    Ahn SS; Irie RF; Weisenburger TH; Jones PC; Juillard G; Roe DJ; Morton DL
    Surgery; 1982 Aug; 92(2):362-7. PubMed ID: 7101129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
    Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
    Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
    Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
    Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
    López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
    J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncofetal antigen: a tumor-associated fetal antigen immunogenic in man.
    Irie RF; Giuliano AE; Morton DL
    J Natl Cancer Inst; 1979 Aug; 63(2):367-73. PubMed ID: 88539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
    Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
    van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
    Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].
    Doré JF; Portoukalian J; Berthier-Vergnes O; Jacubovich R; Genève J; Bailly M; Lefthériotis E; Weissbrod A; Mayer M
    Bull Cancer; 1990; 77(9):881-91. PubMed ID: 2224160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
    Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
    Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
    Morton DL
    Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
    Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
    Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
    Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
    Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
    Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in malignant melanomaa.
    Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
    Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors.
    Litvak DA; Gupta RK; Yee R; Wanek LA; Ye W; Morton DL
    J Am Coll Surg; 2004 Jan; 198(1):27-35. PubMed ID: 14698308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.